149 related articles for article (PubMed ID: 16788752)
1. Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases.
Bastiaannet E; Hoekstra OS; Oyen WJ; Jager PL; Wobbes T; Hoekstra HJ
Ann Surg Oncol; 2006 Jul; 13(7):919-26. PubMed ID: 16788752
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Mori A; Doi R; Ikai I; Uemoto S
Surgery; 2008 Jun; 143(6):769-77. PubMed ID: 18549893
[TBL] [Abstract][Full Text] [Related]
3. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
4. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
[TBL] [Abstract][Full Text] [Related]
5. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma.
Bastiaannet E; Hoekstra OS; de Jong JR; Brouwers AH; Suurmeijer AJ; Hoekstra HJ
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1592-8. PubMed ID: 22801730
[TBL] [Abstract][Full Text] [Related]
7. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
Sasaki R; Komaki R; Macapinlac H; Erasmus J; Allen P; Forster K; Putnam JB; Herbst RS; Moran CA; Podoloff DA; Roth JA; Cox JD
J Clin Oncol; 2005 Feb; 23(6):1136-43. PubMed ID: 15718309
[TBL] [Abstract][Full Text] [Related]
8. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
9. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
Maubec E; Lumbroso J; Masson F; Suciu V; Kolb F; Mamelle G; Cavalcanti A; Boitier F; Spatz A; Aupérin A; Leboulleux S; Avril MF
Melanoma Res; 2007 Jun; 17(3):147-54. PubMed ID: 17505260
[TBL] [Abstract][Full Text] [Related]
10. S-100B concentrations predict disease-free survival in stage III melanoma patients.
Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment screening on distant metastases and head and neck cancer patients: Validation of risk factors and influence on survival.
Peters TT; Senft A; Hoekstra OS; Castelijns JA; Witte BI; Leemans CR; de Bree R
Oral Oncol; 2015 Mar; 51(3):267-71. PubMed ID: 25552384
[TBL] [Abstract][Full Text] [Related]
12. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy.
Xue F; Lin LL; Dehdashti F; Miller TR; Siegel BA; Grigsby PW
Gynecol Oncol; 2006 Apr; 101(1):147-51. PubMed ID: 16263155
[TBL] [Abstract][Full Text] [Related]
13. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma.
Brountzos EN; Panagiotou IE; Bafaloukos DI; Kelekis DA
Oncol Rep; 2003; 10(2):505-10. PubMed ID: 12579298
[TBL] [Abstract][Full Text] [Related]
14. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer.
Lee JW; Jo K; Cho A; Noh SH; Lee JD; Yun M
J Nucl Med; 2015 Oct; 56(10):1494-500. PubMed ID: 26251414
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
18. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
Clark PB; Soo V; Kraas J; Shen P; Levine EA
Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer.
Lee JW; Jeon S; Mun ST; Lee SM
Int J Gynecol Cancer; 2017 May; 27(4):776-783. PubMed ID: 28333846
[TBL] [Abstract][Full Text] [Related]
20. Value of anatomic site, histology and clinicopathological parameters for prediction of lymph node metastasis and overall survival in head and neck melanomas.
Ettl T; Irga S; Müller S; Rohrmeier C; Reichert TE; Schreml S; Gosau M
J Craniomaxillofac Surg; 2014 Jul; 42(5):e252-8. PubMed ID: 24216129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
